Life-changing therapies

Pipeline
Collaborations
About us

Latest news

• Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin

• Polyphor to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Treatment of HER2 Negative Metastatic Breast Cancer

See all news

Pipeline

Immuno-Oncology

Balixafortide (POL6326)
CXCR4 Inhibitor; metastatic breast cancer in combination with eribulin

Fast Track Designation granted by FDA

Phase III

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Balixafortide (POL6326)
CXCR4 Inhibitor; other conditions/indications

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Cystic Fibrosis / Respiratory

Inhaled Murepavadin – Pseudomonas infections in CF

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Antibiotics

OMPTA platform –  targeting Gram-negative resistant pathogens

 

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Thanatin Derivatives

 

Preclinical

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Other

Cystic Fibrosis

POL6014 –Inhaled Elastase Inhibitor

Outlicensed to Santhera Pharmaceuticals 14.02.2018

Phase I

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Macrocycle discovery platform

New modalities to address challenging biological targets

Learn more